At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
Sitravatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Single-dose, Randomized Crossover Study to Evaluate the Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Sitravatinib for Tumor. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The primary objective of the study was to investigate the relative bioavailability and pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations following oral administration in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumor
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartJul 2020
Primary CompletionNov 2020
TodayJul 2026
First PostedJul 15, 2020
Enrollment StartJul 23, 2020
Primary CompletionNov 9, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.0 years ago
Interventions
Sitravatinibdrug
Administered orally as a free base capsule
Sitravatinibdrug
Administered orally as a malate salt capsule